Literature DB >> 11120990

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

S Arikan1, M Lozano-Chiu, V Paetznick, J H Rex.   

Abstract

We investigated the relevance of prominent reduction in turbidity macroscopically (MIC) and formation of aberrant hyphal tips microscopically (minimum effective concentration; MEC) in measuring the in vitro activity of caspofungin against Aspergillus and Fusarium. Caspofungin generated low MICs and MECs against Aspergillus, but not for Fusarium. While MICs increased inconsistently when the incubation time was prolonged, MEC appeared as a stable and potentially relevant endpoint in testing in vitro caspofungin activity.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11120990      PMCID： PMC90285          DOI： 10.1128/AAC.45.1.327-330.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  Treatment of murine disseminated candidiasis with L-743,872.

Authors:  J R Graybill; L K Najvar; M F Luther; A W Fothergill
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.

Authors:  M Del Poeta; W A Schell; J R Perfect
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species.

Authors:  J A Vazquez; M Lynch; D Boikov; J D Sobel
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

4.  In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions.

Authors:  P W Nelson; M Lozano-Chiu; J H Rex
Journal:  J Med Vet Mycol       Date:  1997 Jul-Aug

5.  In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.

Authors:  O Uzun; S Kocagöz; Y Cetinkaya; S Arikan; S Unal
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans.

Authors:  T V Krishnarao; J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

7.  Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.

Authors:  S P Franzot; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

8.  In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.

Authors:  G G Zhanel; J A Karlowsky; G A Harding; T V Balko; S A Zelenitsky; M Friesen; A Kabani; M Turik; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

9.  Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection.

Authors:  D W Denning; S A Radford; K L Oakley; L Hall; E M Johnson; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1997-09       Impact factor: 5.790

10.  Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.

Authors:  M E Ernst; M E Klepser; E J Wolfe; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  1996 Nov-Dec       Impact factor: 2.803
View more
  67 in total

1.  Comparative evaluation of disk diffusion with microdilution assay in susceptibility testing of caspofungin against Aspergillus and Fusarium isolates.

Authors:  Sevtap Arikan; Victor Paetznick; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

2.  What's New in Antifungals?

Authors:  John M. Valgus
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

3.  Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species.

Authors:  Frank C Odds; Mary Motyl; Roberto Andrade; Jacques Bille; Emilia Cantón; Manuel Cuenca-Estrella; Amanda Davidson; Christian Durussel; David Ellis; Elyse Foraker; Annette W Fothergill; Mahmoud A Ghannoum; Robert A Giacobbe; Miguel Gobernado; Rosemary Handke; Michel Laverdière; Wendy Lee-Yang; William G Merz; Luis Ostrosky-Zeichner; Javier Pemán; Sophia Perea; John R Perfect; Michael A Pfaller; Laurie Proia; John H Rex; Michael G Rinaldi; Juan-Luis Rodriguez-Tudela; Wiley A Schell; Christine Shields; Deanna A Sutton; Paul E Verweij; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

Review 4.  In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection.

Authors:  William J Steinbach; John R Perfect; Wiley A Schell; Thomas J Walsh; Daniel K Benjamin
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 5.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

6.  The composition of the culture medium influences the β-1,3-glucan metabolism of Aspergillus fumigatus and the antifungal activity of inhibitors of β-1,3-glucan synthesis.

Authors:  Cécile Clavaud; Anne Beauvais; Lise Barbin; Hélène Munier-Lehmann; Jean-Paul Latgé
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

7.  Antifungal susceptibility profile of human-pathogenic species of Lichtheimia.

Authors:  Ana Alastruey-Izquierdo; Isabel Cuesta; Grit Walther; Manuel Cuenca-Estrella; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

8.  Albumin Enhances Caspofungin Activity against Aspergillus Species by Facilitating Drug Delivery to Germinating Hyphae.

Authors:  Petros Ioannou; Aggeliki Andrianaki; Tonia Akoumianaki; Irene Kyrmizi; Nathaniel Albert; David Perlin; George Samonis; Dimitrios P Kontoyiannis; Georgios Chamilos
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

9.  Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.

Authors:  William R Kirkpatrick; Sofia Perea; Brent J Coco; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration.

Authors:  Jeff Fuller; Adam Schofield; Safeer Jiwa; Crystal Sand; Brad Jansen; Robert Rennie
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.